[This Week's IPO] Demand Forecast and Subscription Schedule for the Third Week of September

This month, during the third week of September, Myungin Pharmaceutical is set to begin its public subscription for retail investors.

<Public Subscription>

◆Myungin Pharmaceutical = The desired offering price band is between 45,000 and 58,000 won, with the total offering amount ranging from 153 billion to 197.2 billion won. The demand forecast will run until September 15, and the public subscription for retail investors will be held over two days, from September 18 to 19. KB Securities is serving as the lead underwriter.

Myungin Pharmaceutical, widely known for products such as Igatan and MaykinQ, was established in April 1985 and holds the largest specialized portfolio in the domestic central nervous system (CNS) therapeutics sector. The company currently offers over 200 types of CNS therapeutics, including 31 exclusive drugs, giving it the broadest lineup in the country. Based on this, it has secured the top position in the CNS sector for two consecutive years, maintaining its market leadership.